Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19923485 | 0.80 | MEN1 (0.32) | KMT2AMEN1 | |
| SCHEMBL19923512 | 0.79 | NPC1 (0.47) | KMT2AMEN1GAAMAPT | |
| SCHEMBL19923473 | 0.78 | GRM4 (0.45) | ALDH1A1TSHRKMT2AUSP2MAPT | |
| SCHEMBL19923712 | 0.78 | ACHE (0.35) | PLA2G7KMT2AMEN1 | |
| SCHEMBL19923482 | 0.73 | ENPP2 (0.48) | ALDH1A1TSHRKMT2AMEN1GAA | |
| SCHEMBL19923636 | 0.71 | ALDH1A1 (0.43) | ALDH1A1TSHRKMT2AMEN1GAA | |
| SCHEMBL19923660 | 0.70 | PLA2G7 (0.33) | PLA2G7BRD4KMT2A | |
| SCHEMBL11276548 | 0.68 | ENPP2 (0.49) | PLA2G7ALDH1A1KMT2AMEN1GAA | |
| SCHEMBL19923638 | 0.67 | PLA2G7 (0.45) | PLA2G7ALDH1A1GAAHSD17B10L3MBTL1 | |
| SCHEMBL19923649 | 0.66 | KMT2A (0.33) | PLA2G7ALDH1A1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | PLA2G7 2819/4885BRD4 391/4885ALDH1A1 2648/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | PLA2G7 2655/4885BRD4 490/4885ALDH1A1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.